Background illustration for clinical trials search

Vaccines Clinical Trials

Find clinical trials for vaccines. Search for vaccines clinical trials in different cities and states across the United States.

Filter

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

for
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,
Location: Atlanta GA
Sponsor: Emory University

Sex: All

Age: 18+

Code: NCT06636734

Phase 2, Recruiting

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

for
Triple Negative Locally Advanced Non-resectable Breast Cancer,
Location: Boston MA, Toronto, Columbus OH, Nashville TN,
Sponsor: Marengo Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06827613

Phase 1, Phase 2, Recruiting

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

for
Advanced Solid Tumors, HER2 Mutation
Location: Boston MA, Toronto, Fort Myers FL, Cleveland OH,
Sponsor: Bayer

Sex: All

Age: 18+

Code: NCT06760819

Phase 2, Recruiting

A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors

for
HER-2 Positive Advanced Solid Tumors
Location: New York NY
Sponsor: D3 Bio (Wuxi) Co., Ltd

Sex: All

Age: 18+

Code: NCT05957536

Phase 1, Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

for
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma,
Location: New Haven CT, The Bronx NY, New York NY,
Sponsor: QuantumLeap Healthcare Collaborative

Sex: All

Age: 18+

Code: NCT01042379

Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

HPV Self-Collection Program

for
HPV
Location: Salt Lake City UT
Sponsor: University of Utah

Sex: Female

Age: 25 - 65

Code: NCT06674681

Recruiting

Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

for
Breast Cancer, Locally Advanced Breast Cancer,
Location: Stony Brook NY
Sponsor: Alison Stopeck

Sex: Female

Age: 18+

Code: NCT06220214

Early Phase 1, Recruiting

Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.

for
Vulvar Cancer, Cervical Cancer, Vulvar Dysplasia,
Location: Toronto
Sponsor: Dr. Danielle Vicus

Sex: Female

Age: 40+

Code: NCT03061435

Recruiting

Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients

for
Hematopoietic and Lymphoid Cell Neoplasm, Influenza
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 12+

Code: NCT04712539

Phase 2, Recruiting

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

for
Adenocarcinoma of the Rectum,
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT05672524

Phase 2, Recruiting

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

for
ER-Positive Breast Cancer, HER2-negative Breast Cancer
Location: Houston TX
Sponsor: The Methodist Hospital Research Institute

Sex: All

Age: 18+

Code: NCT05305924

Phase 2, Recruiting

Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

for
HPV-Associated Oropharyngeal Squamous Cell Carcinoma,
Location: Boston MA
Sponsor: Jonathan Schoenfeld, MD, MPH

Sex: All

Age: 22+

Code: NCT04900623

Phase 2, Recruiting

Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer

for
HER2-positive Breast Cancer
Location: Lee's Summit MO, Kansas City MO, Kansas City KS,
Sponsor: Qamar Khan

Sex: Female

Age: 18+

Code: NCT03238495

Phase 2, Recruiting

COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

for
COVID 19, Influenza, Rheumatoid Arthritis (RA),
Location: Montreal
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Sex: All

Age: 18+

Code: NCT06599658

Phase 2, Recruiting

Screening for LID Clinical Studies Unit Healthy Volunteer Protocols

for
Zika, Influenza
Location: Bethesda MD
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Sex: All

Age: 18 - 65

Code: NCT01386424

Recruiting

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

for
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,
Location: Jacksonville FL, Rochester MN, Scottsdale AZ
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT05541016

Phase 2, Recruiting

Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

for
HPV-Negative Squamous Cell Carcinoma
Location: Chicago IL
Sponsor: University of Chicago

Sex: All

Age: 18+

Code: NCT06005324

Phase 1, Recruiting

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

for
Metastatic Breast Cancer, HER2-negative Breast Cancer
Location: Kansas City MO
Sponsor: Saint Luke's Health System

Sex: All

Age: 18 - 65

Code: NCT05025735

Phase 2, Recruiting

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

for
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,
Location: Atlanta GA
Sponsor: Emory University

Sex: All

Age: 18+

Code: NCT06662058

Recruiting

A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand

for
HSIL, High Grade Squamous Intraepithelial Lesions, Anal Cancer,
Location: New York NY
Sponsor: Stephen E. Goldstone

Sex: All

Age: 18 - 70+

Code: NCT03302858

Phase 2, Recruiting

What vaccine clinical trials are studying now

New flu vaccines. Moderna's mFlusiva, approved August 5, 2026 for adults 50 and older, is the first mRNA flu vaccine. In its Phase 3 trial it prevented about 27 percent more flu cases than a standard dose vaccine, with more short term side effects. Flu vaccine studies, including human challenge trials, are listed on our influenza clinical trials page.

Vaccines in pregnancy. Vaccinating a mother so antibodies pass to the baby is one of the most active areas of research. A Phase 3 trial of a group B streptococcus vaccine, a leading cause of serious infection in newborns, is recruiting pregnant participants at 120 US sites.

Pneumococcal and other bacterial vaccines. Next generation vaccines that cover more strains of the bacteria behind pneumonia and meningitis, tested against the vaccines in use today. Two pneumococcal vaccine studies are enrolling healthy adults 18 to 75 who have never had a pneumococcal vaccine.

RSV vaccines. Combination and revaccination studies, covered on our RSV vaccine clinical trials page. Studies of new flu and RSV vaccines for adults 60 and older are enrolling now.

Cancer vaccines. These do not prevent cancer; they teach the immune system to attack a cancer that is already there. Intismeran, made for each patient from up to 34 mutations in their own tumor, met its main goal in a Phase 3 melanoma trial in August 2026 but is not yet approved. Smaller studies test vaccines for HER2 positive breast cancer, liver cancer, and HPV related cancers; see our melanoma and breast cancer pages.

COVID-19. Updated formulas are approved each season; the 2026 to 2027 mRNA formula is approved for adults 65 and older and for people 5 to 64 with a condition that raises their risk. One study is testing a COVID-19 vaccine given during an active infection, for people 12 and older who tested positive within the past 5 days and have a risk factor for severe illness; it measures the immune response and is not a treatment for the current illness. Studies of COVID-19 and long COVID are on our COVID-19 page.

Vaccines for infections that have none yet. There is still no approved vaccine against Epstein-Barr virus, the cause of mono, or against C. difficile, a common hospital infection. A study of an EBV vaccine is enrolling healthy adults 18 to 30, and C. diff vaccine studies are enrolling adults 65 and older who have frequent contact with healthcare but have never had the infection.

Human challenge studies. Healthy adults receive a vaccine or placebo, then a controlled dose of a virus such as influenza, in a monitored setting. They answer in weeks what field trials take seasons to show.

Article preview image

65 or older? Read our guide: Not All Flu Vaccines Work the Same After 65: Which to Choose and When to Get It

Not All Flu Vaccines Work the Same After 65: Which to Choose and When to Get It

How vaccine trials differ from drug trials

Who can participate in vaccine clinical trials?

Do vaccine trial participants get paid?

How to enroll in a vaccine clinical trial